Advinus Therapeutics Limited, a research-based pharmaceutical company, provides drug discovery, and pharmaceutical and agrochemical development services in India. The company’s drug discovery services include developing small molecule therapies for indications in metabolic diseases, such as diabetes and obesity; inflammatory diseases, including chronic obstructive pulmonary diseases, inflammatory bowel diseases, and autoimmune disorders; pain/degenerative diseases, which comprise Parkinson’s diseases; and neglected diseases, such as leishmaniasis, dengue fever, tuberculosis, leprosy, and malaria. Its pharmaceutical development services include process development and synthesis, process chemi...
21 & 22 Phase II
Peenya Industrial Area
Bengaluru, 560 058
Founded in 2005
Advinus Therapeutics Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Advinus Therapeutics Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Advinus Therapeutics Limited Presents at The China Global Investment Summit: Hangzhou, Oct-16-2014 09:15 AM
Sep 11 14
Advinus Therapeutics Limited Presents at The China Global Investment Summit: Hangzhou, Oct-16-2014 09:15 AM. Venue: Hyatt Regency Hangzhou, Hangzhou, China. Speakers: Ramabadran Gopalakrishnan, Chairman of the Board.
Advinus Therapeutics Limited Reports Unaudited Earnings Results for the Year Ended March 31, 2014
May 31 14
Advinus Therapeutics Limited reported unaudited earnings results for the year ended March 31, 2014. For the period, the company reported revenue was INR 1,544,976,958 against INR 1,290,716,834 a year ago. Earnings before interest, tax, depreciation and amortization was INR 114,844,726 against INR 133,691,107 a year ago. Loss before tax was INR 367,775,831 against INR 317,501,464 a year ago. Loss after tax was INR 367,775,831 against INR 317,501,464 a year ago. Loss per share was INR 2.75 against INR 2.38 a year ago. Net cash generated from operating activities was INR 248,516,688 against INR 22,841,186 a year ago. Capital expenditure on fixed assets, including capital advance was INR 80,621,764 against INR 26,436,734 a year ago.